Table 4.
Past studies on salvage RT for biochemical recurrence after RP
| Study | Patients (n) | Median pre-RT PSA (ng/ml) | prognostic factors after salvage RT | bRDS(%) |
|---|---|---|---|---|
| Hagan et al [7] | 91 | 4.5 | pre-RT PSA (< 1.0 ng/ml) | 55 (5-year) |
| Quero et al [8] | 59 | 1.43 | pre-RT PSA (< 1.0 ng/ml) | 41.2 (5-year) |
| Macdonald et al [9] | 121 | 1.4 | pre-RT PSA (< 0.2 ng/ml) | NA |
| Anscher et al [10] | 89 | 1.4 | pre-RT PSA (< 2.5 ng/ml), RT dose (> 65 Gy) | 50 (4-year) |
| Chawla et al [20] | 54 | 1.3 | Gleason score (≤ 6), time to detectable postoperative PSA | 35 (5-year) |
| Tsien et al [21] | 57 | 1.2 | Gleason score (< or = 7) | 58 (5-year) |
| Neuhof et al [4] | 171 | 1.1 | Gleason score (< 7), pre-RT PSA (< 1.0 ng/ml) | 35.1 (5-year) |
| Jacinto et al [22] | 43 | 0.87 | PSADT (> 4.0 months) | 71 (3-year) |
| Taylor et al [23] | 66 | 0.8 | delayed rise in PSA after RP | 66 (5-year) |
| Pazona et al [11] | 307 | 0.8 | pre-RT PSA (< 1.3 ng/ml), Seminal vesicle | 40 (5-year) |
| Stephenson et al [6] | 501 | 0.72 | Gleason score (≤ 7), pre-RT PSA (≤ 2.0 ng/ml), PSADT (> 10 months) |
45 (4-year) |
| Buskirk et al [12] | 368 | 0.7 | pT2-3a, Gleason score (≤ 7), Pre-RT PSA (< 1.0 ng/ml) | 46 (5-year) |
| Bernard et al [13] | 364 | 0.6 | RT dose (> 66.6 Gy, patients with pre-RT PSA < 0.6 ng/ml) | 50 (5-year) |
| Ward et al [24] | 211 | 0.6 | PSADT (> 12 months) | 34 (10-year) |
| King et al [25] | 37 | 0.49 | PSAV (≤ 1.0 ng/ml/year) | NA |
| Wiegel et al [26] | 162 | 0.33 | PSA undetectable after salvage RT (< 0.1 ng/ml) | 54 (3.5-year) |
| Tomita et al [27] | 51 | 0.25 | PSADT (> 3.0 months), Gleason Score, RT dose (≥ 60 Gy) | 55.1 (3-year) |
| Terai et al [14] | 37 | 0.146 | cT1-2, pT2, pre-RT PSA (> 0.15 ng/ml) | 54 (5-year) |
Abbreviations: RT = radiotherapy, RP = radical prostatectomy, PSA = prostate-specific antigen, bRDS = biochemical relapse-free survival, PSADT = PSA doubling time, PSAV = PSA velocity, NA = not available